Theravance, Inc. (NASDAQ: THRX) reported Q3 EPS of ($0.44), $0.35 better than the analyst estimate of ($0.79). Revenue for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE